Trio sequencing analyzes an affected individual together with both biological parents. Its principal advantage is interpretive: the laboratory can assess inheritance directly while reviewing the child’s variants. This can make it easier to identify newly arisen variants, establish relationships between recessive candidates and filter implausible explanations.
More information, not a universal yield guarantee
A head-to-head study of trio and singleton exome analysis found that parental data reduced the number of variants requiring curation. The incremental diagnostic gain in that study was relatively modest, and the authors linked this partly to an experienced, clinically integrated singleton workflow. The result illustrates why yield comparisons depend on the baseline service rather than only the number of people sequenced. Read the comparative study.
Trio analysis may save interpretive effort even when the final diagnostic yield changes little. Conversely, sequencing three people does not repair every coverage gap or make a difficult variant class detectable. Test scope and family structure should be considered separately.
De novo does not mean automatically causal
The Deciphering Developmental Disorders study demonstrated the importance of de novo variation in severe developmental disorders. Its large-scale analysis relied on family data and statistical evidence across genes. An individual variant absent from parental samples still requires assessment of the gene, mechanism, phenotype and technical quality before it can be interpreted as causative. Read the DDD study.
The word de novo also needs context. Absence from the sampled parental tissue at the assay’s detection limit does not exclude every form of parental mosaicism. It therefore should not be translated into a statement of zero recurrence risk. Likewise, a negative trio result does not rule out a genetic disorder.
Prepare the family and the laboratory
- Provide a clear phenotype and pedigree rather than relying on parental data alone.
- Discuss consent for each participant and the laboratory’s policy on unexpected family information.
- Clarify how the service handles secondary findings in parents.
- Ask what alternatives are available when one or both parents cannot participate.
For clinical communication, distinguish inheritance evidence from the final diagnosis. A trio can make the evidence more informative and efficient to evaluate, but a molecular conclusion still rests on the full case. Recording why parental data changed the interpretation makes that conclusion easier to review and explain.